HEC81885 Tosylate

1. Primary objectives: 1) To evaluate the safety and tolerability of HEC81885 p-toluenesulfonate in subjects with advanced solid tumors; to observe dose-limiting toxicity (DLT), determine the maximum tolerated dose (MTD) or extended recommended dose (RED), and provide a basis for the recommended dosage and dosing regimen of subsequent clinical trials of HEC81885 p-toluenesulfonate; 2) To evaluate the efficacy of HEC81885 p-toluenesulfonate in advanced solid tumors. 2. Secondary objectives: 1) To observe the pharmacokinetic characteristics of HEC81885 p-toluenesulfonate in humans and identify its main metabolites; 2) To observe the correlation between the overexpression of c-Met and Axl proteins in tumor tissues, and the amplification or mutation of c-Met or other genes and the efficacy of HEC81885 p-toluenesulfonate.